Overview

NVX-108 Combined With Radiation & TMZ, and During Maintenance Phase for Newly-diagnosed Glioblastoma Multiforme

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy. NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
NuvOx LLC
NuvOx Pharma Pty Ltd